MedTrace Logo

Propofol for Supreme LMA Insertion With and Without Remifentanil

NCT01974648 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2013-11-01

No results posted yet for this study

Summary

The aims of this study were to determine the clinically required concentration of propofol for LMA Supreme insertion, and to examine to what extent remifentanil reduces the dose of propofol and improves conditions for it's insertion.

Conditions

  • Patients Requiring Ambulatory Surgery Under General Anesthesia

Interventions

DRUG

propofol

DRUG

propofol and remifentanil

Sponsors & Collaborators

  • Ministry of Health, Spain

    collaborator OTHER_GOV

  • Hospital General Universitario Gregorio Marañon

    lead OTHER

Principal Investigators

  • Matilde Zaballos, PhD · Hospital General Universitario Gregorio Marañón

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01974648 on ClinicalTrials.gov